Answer
Ciprofloxacin increased erlotinib exposure (AUC) by 39%, with no statistically significant change in Cmax; active-metabolite AUC and Cmax increased by about 60% and 48%, respectively, but the clinical relevance has not been established.
Sources for this answer
- Tarceva 25 mg, 100 mg & 150 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 11Document updated
Sources checked